




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/15, C07K 14/81, A61K 38/36, 38/55		A2	(11) International Publication Number: WO 99/60126
			(43) International Publication Date: 25 November 1999 (25.11.99)
(21) International Application Number: PCT/US99/07040		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 13 May 1999 (13.05.99)			
(30) Priority Data: 60/086,571 19 May 1998 (19.05.98) US			
(71) Applicant (for all designated States except US): WASHINGTON UNIVERSITY [US/US]; One Brookings Drive, St. Louis, MO 63130 (US).			
(72) Inventor; and (75) Inventor/Applicant (for US only): BROZE, George, J., Jr. [US/US]; Washington University School of Medicine, Dept. of Internal Medicine, Division of Hematology, Barnes-Jewish Hospital of St. Louis, 216 S. Kingshighway Boulevard, St. Louis, MO 63110 (US).			
(74) Agents: MEYER, Scott, J. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680 (US).		Published Without international search report and to be republished upon receipt of that report.	

(54) Title: PROTEIN Z-DEPENDENT PROTEASE INHIBITOR

(57) Abstract

The disclosure describes the purification and isolation of a novel human protein Z-dependent protease inhibitor (ZPI) from plasma characterized as having a molecular weight of about 72 kDa, being a single chain protein with an N-terminal amino acid sequence of LAPSPQSPETPA, and which produces a rapid inhibition of factor Xa in the presence of human protein Z (PZ), calcium ions and cephalin. The disclosure further describes the isolation and cloning of the ZPI cDNA from a human cDNA library. The ZPI cDNA is 2.44 kb in length and has an open reading frame that encodes the 423 residue mature ZPI protein and a 21 residue signal peptide. PZ, ZPI and the combination of PZ and ZPI are used to inhibit blood coagulation.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PROTEIN Z-DEPENDENT PROTEASE INHIBITOR

This is a Continuation-in-Part of Application Ser. No. 60/086,571, filed May 19, 1998.

This invention was made in part with government support under grant numbers HL 34462 and HL 60782 awarded by the National Institutes of Health. The government has certain rights to the invention.

FIELD OF THE INVENTION

The present invention relates to the field of vitamin K-dependent plasma proteins such as the four classical clotting factors (Factors II, VII, IX and X), protein C, protein S and, more particularly, to human protein Z (PZ).

BACKGROUND OF THE INVENTION

[Note: Literature references on the following background information and on conventional test methods and laboratory procedures well-known to the ordinary person skilled in the art, and other such state-of-the-art techniques as used herein, are indicated by numbers in parentheses and appended at the end of the specification.]

Vitamin K is required for the post-translational formation of gamma carboxyglutamic acid (Gla), which is present in a number of plasma proteins that are involved in coagulation: Prothrombin, factors VII, IX, X, protein C and protein S (1,2). Gla-mediated calcium ion binding in these proteins is necessary for their association with phospholipid surfaces and is critical for their hemostatic function (3). In 1977, Prowse and Esnouf identified

-2-

an additional vitamin K-dependent protein circulating in bovine plasma and named it protein Z (PZ) (4). Initially thought to represent a single chain form of bovine factor X, bovine PZ was later identified as a discrete Gla-containing protein (5,6). The human counterpart of bovine PZ was isolated in 1984 (7).

Human PZ is a 62,000 molecular weight glycoprotein that has a plasma half-life of ~2.5 days (8). Plasma PZ levels in blood donors span a broad range with a mean concentration of 2.9 ± 1.0 $\mu\text{g/mL}$ in EDTA anticoagulated samples (corresponding to ~ 2.6 $\mu\text{g/mL}$ in citrate plasma) (8). The amino-terminal half of PZ is very homologous (40-50%) to those of factors VII, IX and X, and contains a Gla-domain, two EGF-like domains, and a region which connects to a homologue of the catalytic domains present in the serine protease zymogens. In the carboxy-terminal domain of PZ, however, the region around the typical "activation" site is absent and the His and Ser residues of the catalytic triad are lacking (the Asp residue is conserved) (9,10).

McDonald et al (11) have recently reported that the kinetics of the binding of human and bovine PZ to phosphatidylcholine/phosphatidylserine (PC/PS=75%/25%) vesicles is different from that of the other vitamin K-dependent coagulation factors. The k_{assn} ($10^{-5} \text{s}^{-1} \text{M}^{-1}$) and k_{dissn} (s^{-1}) rate constants are 1.95 and 0.0063 for bovine PZ and 3.36 and 0.057 for human PZ. In comparison the values of these constants for bovine prothrombin are 176.0 and

-3-

1.9, respectively. Thus, the association and dissociation rate constants for bovine and human PZ are dramatically slower than those of prothrombin and the dissociation of bovine PZ from phospholipids is significantly slower than that of human PZ.

BRIEF DESCRIPTION OF THE INVENTION

The invention relates to human protein Z (PZ) and a novel human protein Z-dependent inhibitor (ZPI).

In accordance with one embodiment of the invention, a novel human protein Z-dependent protease inhibitor (ZPI) has been purified and isolated from plasma and characterized structurally and biologically. ZPI is a 72,000 molecular weight, single chain protein with an initially determined N-terminal amino acid sequence of LAPSPQSPEXXA (X = indeterminant). Using the conventional three-letter amino acid symbols required by 37 CFR §1.821-1.825, the N-terminal sequence is as follows:

Leu Ala Pro Ser Pro Gln Ser Pro Glu Xaa Xaa Ala [SEQ ID NO:1].
1 5 10

This sequence does not match or show significant homology with the sequences accessible in publicly available protein or DNA data bases. Thus, it believed that ZPI is a novel protein.

-4-

ZPI has an estimated concentration in citrate plasma of about 1.0 to 1.6 $\mu\text{g/mL}$. In systems using purified components, the factor Xa inhibition produced by ZPI is rapid (>95% within one minute by bioassay) and required the presence of human protein Z, calcium ions and cephalin. The inhibitory process appears to involve the formation of a factor Xa-PZ-ZPI complex at the phospholipid surface.

To further characterize ZPI in another embodiment of the invention, its cDNA was isolated and cloned from a human liver cDNA library. The ZPI cDNA is 2.44 kb in length and has a relatively long 5' region (466 nt) that contains six potential ATG translation start codons. ATG's 1 to 4 are followed by short open reading frames, whereas ATG₅ and ATG₆ are in an uninterrupted 1335 bp open reading frame that includes the encoded ZPI protein. The deduced ZPI protein of 444 amino acids has a typical 21 residue signal peptide that is followed by the N-terminal sequence of the purified protein in which the initially indeterminate residues 10 and 11 in SEQ ID NO:1 are, respectively, threonine and proline, as in SEQ ID NO: 8.

In vitro experiments show that ATG₆ is sufficient for the expression of rZPI in cultured Chinese hamster ovary (CHO) cells. Northern analysis suggests that the liver is a major site of ZPI synthesis.

-5-

The predicted 423 residue amino acid sequence of the mature ZPI protein is 25-35% homologous with members of the serpin superfamily of protease inhibitors and is 78% identical to the amino acid sequence predicted by a previously described cDNA isolated from rat liver, regeneration-associated serpin protein-1 (rasp-1).

Alignment of the amino acid sequence of ZPI with those of other serpins predicts that Tyr387 (Y387) is the P₁ residue at the reactive center of the ZPI molecule. Consistent with this notion, rZPI (Y387A), an altered form of ZPI in which tyrosine 387 has been changed to alanine, lacks PZ-dependent factor Xa inhibitory activity.

In still other embodiments of the invention, PZ, ZPI and the combination of PZ and ZPI are used as inhibitors of blood coagulation. As illustrated below, this is the first work showing that PZ and ZPI produce inhibition of coagulation. This work also shows that PZ can inhibit coagulation in the absence of ZPI (FIG. 5).

DETAILED DESCRIPTION OF THE INVENTION

While the specification concludes with claims particularly pointing out and distinctly claiming the subject matter regarded as forming the invention, it is believed that the invention will be better understood from the following preferred embodiments of

-6-

the invention taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graphical representation which shows the effect of PZ on the inhibition of factor Xa by antithrombin III. Reactions containing factor Xa (5 nM), CaCl_2 (4 mM), with or without PZ (40 nM), and with or without cephalin (15 μM) were incubated 5 min. at 22° C before the addition of antithrombin III (3.4 μM). At the indicated times thereafter, samples were removed, diluted in HSA with 1mM EDTA, and assayed for factor Xa activity by bioassay.

- (Δ), without cephalin, without PZ;
- (O), without cephalin, with PZ;
- (■), with cephalin, without PZ;
- (●), with cephalin, with PZ.

FIG. 2 is a graphical representation which shows the factor Xa inhibition by serum. Factor Xa (5 nM), CaCl_2 (4 mM), cephalin (15 μM) with or without PZ (40 nM) were incubated 5 min at 22° C before the addition of barium absorbed serum (25% v/v) which had been previously treated for 30 min. with rabbit preimmune or immune anti-ZPI IgG (300 $\mu\text{g/mL}$). At the specified times thereafter, samples of the reactions were diluted in HSA with 1 mM EDTA and assayed for factor Xa activity by bioassay.

-7-

- (●), with PZ and preimmune IgG;
- (▼), with PZ and immune IgG;
- (O), without PZ and with preimmune IgG;
- (▲), without PZ and with immune IgG.

FIG. 3 shows the SDS-Page of purified ZPI. ZPI (5 μ g) was analyzed with (lane 2, right) or without (lane 1, left) reduction with 5% 2-mercaptoethanol. Protein was stained with Coumassie Brilliant Blue. The position of molecular weight standards in kDa is shown on the left.

FIG. 4, in four parts, FIGS. 4A, 4B, 4C and 4D, is a graphical representation which shows the PZ-dependent inhibition of factor Xa by ZPI.

FIG. 4A shows the ZPI dose/response. Reactions containing factor Xa (2.5 or 5.0 nM), CaCl_2 (4 mM), cephalin (15 μ M) and PZ (40 nM) were incubated with increasing concentrations of ZPI for 15 min. at 22° C before remaining factor Xa activity was determined by amidolytic assay. The molar concentration of ZPI was estimated assuming 1.0 mg/mL ZPI produces an A_{280} of 1.0. (\square), factor Xa 2.5 nM; (O), factor Xa 5.0 nM.

FIG. 4B shows the PZ dose/response. Reactions containing factor Xa (2.5 or 5.0 nM), CaCl_2 (4 mM), cephalin (15 μ M)

-8-

and ZPI (10 nM) were incubated with increasing concentrations of PZ for 15 min. at 22° C before remaining factor Xa activity was determined by amidolytic assay. (□), factor Xa 2.5 nM; (○), factor Xa 5.0 nM.

FIG. 4C shows the cephalin dose/response. Reactions containing factor Xa (2.5 nM), CaCl_2 (4 mM), PZ 40 nM, and ZPI 10 nM) were incubated with increasing concentrations of cephalin for 15 min. at 22° C before remaining factor Xa activity was determined by amidolytic assay.

FIG. 4D shows time course of factor Xa inhibition by PZ/ZPI. Reactions containing factor Xa (5.0 nM), with or without CaCl_2 (4 mM), with or without cephalin (15 μM), and with or without PZ (40 nM) were incubated 5 min. at 22° C before the addition of ZPI (10 nM). At the specified times thereafter remaining factor Xa activity was determined by bioassay or amidolytic assay. Bioassay: (●), with all reactants. Amidolytic assay: (■), with all reactants; (▼), without CaCl_2 ; (▲), without cephalin; (◆), without PZ.

FIG. 5 is a graphical representation which shows the effect of anti-ZPI antibodies on factor Xa-induced coagulation of plasma. Reactions (200 μL) containing factor Xa (0.125 nM),

-9-

CaCl₂ (5 mM), cephalin (18.75 μM), with or without PZ (50 nM) were incubated in the sample cup of a fibrometer. After 2 min. at 37° C, 50 μL) of factor X deficient plasma which had been treated with rabbit preimmune IgG (600 μg/mL) or immune anti-ZPI IgG at increasing concentrations for 30 min. was added and the clotting time measured. Apparent factor Xa inhibition (76%) produced by the inclusion of PZ during the preincubation period and using plasma treated with preimmune IgG is listed as maximal PZ-dependent inhibition (100% on the ordinate). The concentration of Anti-ZPI IgG used to treat the plasma is listed on the abscissa.

FIG. 6 shows the nucleotide sequence (SEQ ID NO: 7) and deduced amino acid sequence (SEQ ID NO: 8) of human ZPI cDNA. The amino acid sequence is shown in single letter code beneath the nucleotide sequence. Nucleotide/amino acid numbers are shown in the column at the left. Translation is depicted as starting at ATG₆(nt 467). An alternative initiation codon, ATG₅(nt 347), is underlined in dashes (see Example II). Amino acid sequences derived from purified plasma ZPI are underlined. N* denote potential sites of N-linked glycosylation and the tyrosine residue at the putative P₁ site at the reactive center of ZPI is shown in bold print. The amino acid sequence is shown in three letter code in the attached S quence Listing.

-10-

FIG. 7 shows the Northern analysis of multiple tissues for ZPI mRNA. A Northern blot nitrocellulose membrane containing 2 μ g poly A⁺ mRNA from various human tissues in each lane was hybridized with a ³²P-labeled full length ZPI cDNA probe (above) or a ³²P-labeled β -actin cDNA probe (below).

FIG. 8 shows the alignment of the C-terminal amino acid sequences of ZPI and other serpins. Amino acid sequences of rat rasp-1 (RASP-1) and human α_1 -antitrypsin (A1AT), antitrypsin related sequence (A1AU), antithrombin (AT-III), heparin cofactor II (HC-II), and protease nexin 1 (PN-1) were extracted from the GenBank data base (accession numbers 2143953, 1703025, 112891, 113936, 123055, and 121110, respectively). Identical amino acids are darkly shaded. The arrowhead indicates the column containing the P₁ residue at the reactive center of each serpin.

FIG. 9 shows the Western blot analysis of wild-type and altered forms of recombinant ZPI. Serum-free conditioned media (10 μ L) from non-transfected CHO cells (CHO) and CHO cells expressing rZPI(WT) (Tyr), rZPI(Y387A)(Ala) and rZPI(Y387R) (Arg) were analyzed by 12% SDS-PAGE and Western blotting using a mouse monoclonal anti-ZPI antibody. The migration of pre-stained molecular weight standards listed in kDa is depicted on the left. Below the blot is listed the ZPI activity of each conditioned media (average of duplicate

-11-

measurements). The protein band identified at ~54,000 is detected in the conditioned media of non-transfected CHO cells and appears to be unrelated to rZPI.

In order to illustrate the invention in greater detail, the following specific laboratory examples were carried out. Although specific examples are thus illustrated herein, it will be appreciated that the invention is not limited to these specific, illustrative examples or the details therein.

EXAMPLE I

Purification and Isolation of ZPI from Human Plasma

MATERIALS and METHODS

Materials. Sodium dodecyl sulfate (SDS), HEPES, MES, Trizma Base, Diisopropylfluorophosphate (DFP), Triton X-100, Tween 20, ethylenediaminetetraacetic acid (EDTA), polyethylene glycol (8,000 MW) S Fast Flow, bovine serum albumin, and rabbit brain cephalin were from Sigma Chemical Co. (St. Louis, MO). Mono-Q, Monol-S and heparin-Sepharose were purchased from Pharmacia Biotech (Piscataway, NJ). Low molecular weight standards for polyacrylamide gel electrophoresis were from Bio-Rad Laboratories (Richmond, CA) and protein A-agarose from Repligen (Cambridge, MA). Spectrazyme Xa (MeO-CO-D-CHG-Gly-Arg-pNA.ACOH) was from American Diagnostica, Inc. (Greenwich, CT).

-12-

Plasma/serum. Factor X deficient plasma was purchased from George King Biomedical (Overland Park, KS). To produce serum, fresh blood was allowed to clot for one hour at 37° C, the clot rimmed, and serum collected following centrifugation (10,000 g, 20 min). Barium-absorbed serum was produced by adding sodium oxalate (10 mM final) and two subsequent absorptions with barium sulfate (100 mg/mL, 4° C, 30 min). By monoclonal antibody sandwich immunoassay (8), the barium absorbed serum contained 0.10 µg/mL PZ.

Proteins. Alpha-1-antitrypsin was purchased from Sigma, alpha-2-antiplasmin and thrombin from American Diagnostica, Inc., protein C inhibitor (PCI) from Enzyme Research Laboratories (South Bend, IN), and antithrombin III from Chromogenix AB (Molndal, Sweden). Alpha-2-macroglobulin was a gift from A. Schwartz (Washington University, St. Louis) and heparin cofactor II a gift from D. Tollefsen (Washington University). Inter-alpha-trypsin inhibitor was purified as previously described (12). Prothrombin and factor X were purified and factor Xa was produced from purified factor X using insolubilized X-coagulant protein from Russells viper venom as previously described (13). Additional factor Xa was purchased from Enzyme Research Laboratories.

PZ was isolated from citrated fresh frozen plasma (Missouri-Illinois Regional Red Cross) using a four step

-13-

purification procedure that included barium citrate absorption-elution, ammonium sulfate fractionation, monoclonal antibody anti-PZ immunoaffinity chromatography and Mono-Q anion exchange chromatography. Thrombin-cleaved PZ (PZ_T) was produced by incubating 1 mg/mL PZ with 300 U/mL thrombin in 0.1 M NaCl, 0.05 M Tris-HCl, pH 8.0 for 3 hours at 37° C. The solution was treated with DFP (5mM final) before removing the thrombin by passage through a small column of CG-50 in the same buffer (7). The N-terminal amino acid sequence of PZ_T (~56,000 MW) (7) after SDS-PAGE, transfer to a PVDF-Plus membrane (Micron Separations, Inc., Westborough, MA) and gas-phase sequencing (Applied Biosystems, Foster City, CA) by the Protein Chemistry Laboratory (Washington University) is RYKGGSPXISQPXL (X=indeterminant). Using the conventional three-letter amino acid symbols required by 37 CFR §1.821-1.825, this sequence is as follows:

Arg	Tyr	Lys	Gly	Gly	Ser	Pro	Xaa	Ile	Ser	Gln	Pro	Xaa	Leu
1				5									10

[SEQ ID NO:2].

This amino acid sequence is identical to the sequence of PZ beginning at residue 44 of the mature protein. Thus, thrombin appears to cleave PZ following Arg43 thereby separating the Gla-domain from the remainder of the molecule.

-14-

One-stage, factor Xa-induced coagulation assay. Cephalin (75 μM) 50 μL , 50 μL CaCl_2 (25 mM), 50 μL PZ or PZ_T (160 nM), and 50 μL factor Xa (0.5 nM) are incubated at 37° C in the sample cup of a fibrometer (BBL, Cockeysville, MD). After 2 minutes, 50 μL factor X deficient plasma is added and the clotting time measured. In certain tests the PZ or factor Xa were added at varying times during the preincubation period and the cephalin or PZ reagents were added to the reaction with the factor X deficient plasma (100 μL of 1:1 mixtures). Apparent factor Xa activity is determined by comparing the clotting time with a standard curve constructed using various concentrations of factor Xa in the absence of PZ.

Factor Xa bioassay. Cephalin (75 μM) 50 μL , 50 μL CaCl_2 (25 mM), and 50 μL buffer containing 0.1 M NaCl, 0.05 M HEPES, pH 7.4, and bovine serum albumin (1 mg/mL) (HSA) are incubated at 37° C. After 30 seconds, 50 μL of the sample diluted in HSA with 1 mM EDTA is added followed immediately by 50 μL of factor X deficient plasma. Apparent factor Xa activity is determined by comparing the clotting time with a factor Xa standard curve.

Factor Xa amidolytic assay. Mixtures (100 μL) containing various concentrations of cephalin, PZ, ZPI, factor Xa and Ca^{++} ions in HSA buffer are incubated at 22° C in the wells of a microtiter plate. After the specified period of time, 50 μL

-15-

of Spectrazyme Xa (0.5 mM) is added and the initial rate of substrate cleavage ($A_{405}/\text{min.}$) determined in a Vmax microtiter plate reader (Molecular Devices, Menlo Park, CA). In tests studying the time course of factor Xa inhibition by PZ/ZPI, the solution containing the Spectrazyme Xa (0.5 mM) also contained 15 mM EDTA and 0.3 M Tris-HCl, pH 8.3. Factor Xa activity is determined by comparing the initial rate of substrate cleavage with a standard curve produced with various concentrations of factor Xa in the same buffer conditions.

Two-stage factor Xa inhibition assay. To measure ZPI functional activity 10 μL cephalin (75 μM), 10 μL CaCl_2 (25 mM), 10 μL PZ (200 nM), 10 μL of the sample to be tested diluted in HSA, and 10 μL factor Xa (2.5 nM) are incubated in the sample cup of a fibrometer at 37° C. After 60 seconds, 50 μL HSA, 50 μL cephalin (75 μM), 50 μL CaCl_2 (25 mM) and 50 μL factor X deficient plasma are added in succession and the clotting time measured. ZPI activity is determined by comparing the clotting time with a standard curve produced using various concentrations of purified ZPI. The activity of 1 μg purified ZPI was arbitrarily assigned a value of 1 unit.

Purification of ZPI. Human citrate fresh frozen plasma (2.3 liters) from the Missouri-Illinois Regional Red Cross was thawed at 37° C and transferred to the cold room. A six-step purification was carried out as follows:

-16-

1. Barium citrate adsorption and ammonium sulfate fractionation (4° C). 230 mL of 1.0 M BaCl₂ was added dropwise over 45 minutes and the mixture was stirred an additional 15 min. The barium citrate precipitate was removed by centrifugation at 3,000 g for 20 min. and supernatant plasma collected. Ammonium sulfate was added to 45% saturation and the mixture stirred for 30 min. before the precipitate was removed by centrifugation at 10,000 g for 20 min. Sufficient ammonium sulfate was added to bring the supernatant to 75% saturation and the mixture stirred for 30 min. before centrifugation at 10,000 g for 20 min. The protein precipitate was dissolved in 0.1 M NaCl, 0.05 M Tris-HCl, pH 7.5, treated with DFP (1 mM) and dialyzed overnight against the same buffer.

2. Polyethylene glycol (PEG) fractionation (22° C). Sufficient 50% w/v PEG (8,000 MW) was added dropwise to the sample to produce a PEG concentration of 7.5% and the mixture stirred for 30 min. before the precipitate was removed by centrifugation at 10,000 g for 20 min. PEG (50% w/v) was added dropwise to the supernatant solution to produce a PEG concentration of 18.5% and the mixture stirred for 30 min. before centrifugation at 10,000 g for 20 min. The protein precipitate was dissolved in 0.1 M NaCl, 0.020 M MES, pH 6.15 and treated with DFP (1 mM).

-17-

3. S Fast Flow cation exchange chromatography (4° C).

The sample was applied at flow rate of 150 mL/hr to a 5 x 47 cm. column of S Fast Flow equilibrated in 0.1 M NaCl, 0.02 M MES, pH 6.15. The column was washed with 1.5 L of the same buffer and then eluted with a linear gradient to 0.5 M NaCl, 0.02 M MES, pH 6.15 over 8 L. Fractions containing ZPI activity, which eluted at ~0.25 M NaCl, were combined and the pool concentrated to 25 mL (YM 10, Amicon, Danvers, MA) and treated with DFP (5 mM).

4. Mono-Q anion exchange chromatography (22° C). The

concentrated sample was diluted 2.5-fold with 0.02 M MES, pH 6.15 and applied at a flow rate of 1.5 mL/min. to a 10 mL Mono-Q column equilibrated in 0.1 M NaCl, 0.02 M MES, pH 6.15 containing 0.1% (v/v) Tween-20. The column was washed with 15 mL of the same buffer and then eluted with a linear gradient to 0.5 M NaCl in the same buffer over 100 mL. Fractions containing ZPI activity, which eluted at ~0.18 M NaCl were combined and treated with DFP (5 mM).

5. Heparin-Sepharose affinity chromatography (22° C). The

sample was diluted 2-fold with 0.02 M MES, pH 6.15 and applied at a flow rate of 1 mL/min. to a 5 mL heparin-Sepharose column equilibrated in 0.1 M NaCl, 0.02 M MES, pH 6.15 containing 0.1% (v/v) Tween-20. The column was washed with 10 mL of the same buffer and then eluted with a linear gradient to 0.6 M

-18-

NaCl in the same buffer over 50 mL. Fractions containing ZPI activity, which eluted at ~0.25 M NaCl, were pooled and treated with DFP (5 mM).

6. Mono-S cation exchange chromatography (22° C). The sample was diluted 3-fold with 0.02 M MES, pH 6.15 and applied at a flow rate of 0.5 mL/min. to a 1 mL Mono-S column equilibrated in 0.1 M NaCl, 0.02 M MES, pH 6.15 containing 0.01% (v/v) Tween-20. The column was washed with 2 mL of the same buffer and then eluted with a linear gradient to 0.5 M NaCl in the same buffer over 20 mL. Fractions containing ZPI activity, which eluted at ~0.25 M NaCl, were pooled and the purified ZPI stored at -70° C in small aliquots. The molar concentration of ZPI was estimated assuming a ZPI concentration of 1.0 mg/mL produces an absorbance of 280 nm (A_{280}) of 1.0 and a molecular weight of 72,000.

The foregoing six-step purification of ZPI is summarized in Table II, below.

Other Methods. SDS polyacrylamide gel electrophoresis (SDS-PAGE) was performed using the method of Laemmli (14). Rabbit polyclonal anti-ZPI antibodies were developed as previously described using purified ZPI as immunogen (15). Pre-immune and immune IgG were isolated using protein A-agarose. N-terminal amino acid sequence analysis of purified ZPI was performed by

-19-

the Protein Chemistry Laboratory (Washington University) using a gas-phase sequenator (Applied Biosystems). Two separate analyses were performed with 0.3 nmol of ZPI and gave identical results. The phospholipid content of the rabbit brain cephalin was determined as inorganic phosphate (16).

RESULTS

Reduction in Factor Xa procoagulant activity in the presence of PZ, Ca++ ions and phospholipids.

Initial studies investigating the potential function of human PZ showed that the apparent procoagulant activity of factor Xa in a one-stage plasma coagulation assay was reduced if the factor Xa was first incubated with PZ (Table I). The inhibitory effect was time dependent, required the presence of calcium ions and procoagulant phospholipids (rabbit brain cephalin), and appeared predominantly related to the period of preincubation of PZ with phospholipids (Table I). Thrombin treatment of PZ, which cleaves PZ at Arg43 and separates the Gla domain from the remainder of the molecule (see Methods), abolished the inhibitory effect. These results suggest that an interaction between factor Xa and PZ may occur at the phospholipid surface. Consistent with this belief, the rate of inhibition of factor Xa by antithrombin III was slowed by PZ in the presence of cephalin and Ca++ ions ($t_{1/2}$ 35 min. vs. 15 min.) (FIG. 1).

-20-

To further evaluate the effect of PZ on factor Xa inactivation, the time course of the loss of factor Xa activity in PZ-depleted serum with and without added PZ in the presence of cephalin and CaCl_2 was determined by bioassay (FIG. 2). An additional early loss of factor Xa activity is demonstrable in the presence of PZ suggesting that serum contains a PZ-dependent factor Xa inhibitor(s). However, the curves describing the loss of factor Xa activity in serum in the presence and absence of PZ intersect so that ultimately the factor Xa activity remaining in serum with PZ is greater than that in serum without PZ. In systems containing purified proteins, PZ does not enhance the inhibition of factor Xa by alpha-1-antitrypsin, protein C inhibitor, alpha-2-antiplasmin, heparin cofactor II, inter-alpha-trypsin inhibitor or alpha-2-macroglobulin.

Isolation of ZPI

A two-stage bioassay designed to measure PZ-dependent factor Xa inhibition was used to isolate a PZ-dependent protease inhibitor (ZPI) from plasma (Methods, Table II). The ZPI activity of the starting plasma could not be measured due to thrombin generation and fibrin formation during the first stage of the two-stage factor Xa inhibition assay. Nevertheless, assuming a 50% - 75% recovery of ZPI following ammonium sulfate fractionation of plasma (Table II), it is estimated that the plasma concentration of ZPI is 1.0 - 1.6 $\mu\text{g/mL}$ (14-22 nM).

-21-

By SDS-PAGE analysis, ZPI migrates as a single chain protein with an apparent molecular weight of 72 kDa (FIG. 3). Preliminary characterization of the purified protein shows that ZPI activity is abolished by treatment with SDS (1%), urea (8 M), and 2-mercaptoethanol (5% v/v), but is stable in Tween-20 (2%) and Triton X-100 (2%). ZPI is also unaffected by methylamine treatment under conditions that completely inactivate alpha-2-macroglobulin. The N-terminal amino acid sequence of ZPI is LAPSPQSPEXXA (X=indeterminant), SEQ ID NO: 1. This sequence does not match nor show significant homology with the sequences accessible in publicly available protein or DNA data bases. Thus, ZPI may represent a previously unidentified gene-product.

PZ-dependent inhibition of factor Xa by ZPI.

To further investigate the factor Xa-ZPI interaction, mixtures containing factor Xa, CaCl_2 , cephalin and PZ were incubated with increasing concentrations of ZPI for 15 minutes (22° C) (FIG. 4A). The remaining factor Xa activity was then determined in an amidolytic assay (Methods) following the addition of Spectrazyme Xa. The results suggest a high affinity interaction between ZPI and factor Xa with a stoichiometry of 1.2:1 (ZPI:factor Xa). Even at relatively high concentrations of ZPI, however, a significant amount (~20%) of factor Xa amidolytic activity persists.

-22-

The PZ-dose/response of ZPI-mediated factor Xa inhibition was evaluated in similar reactions (FIG. 4B). Again an apparent stoichiometric relationship between PZ and factor Xa was demonstrated with a molar ratio of 1.4:1 (PZ:factor Xa). Optimal PZ-dependent inhibition of factor Xa by ZPI occurs at concentration of mixed rabbit brain phospholipids (cephalin) of $\geq 15 \mu\text{M}$ (FIG. 4C). The inhibition of factor Xa produced by ZPI is rapid following the incubation of factor Xa with PZ, Ca^{++} ions and cephalin (FIG. 4D). Maximal factor Xa inhibition as assessed by amidolytic assay (70%) and bioassay (97%) is reached within <1 minute. Using the amidolytic assay (FIG. 3D) or bioassay, no factor Xa inhibition occurs if PZ, phospholipids, or Ca^{++} ions (1 mM EDTA) is omitted from the reactions.

Serum and plasma were treated with rabbit polyclonal anti-ZPI antibodies to determine the contribution of serum ZPI to the early, enhanced inhibition of factor Xa produced in the presence of PZ and the contribution of plasma ZPI to the apparent reduction in factor Xa activity produced by its incubation with PZ, phospholipids and Ca^{++} ions prior to the one-stage bioassay. Treatment with anti-ZPI antibodies completely abrogated the PZ-dependent factor Xa inhibition in serum (FIG. 2), but reduced the PZ-mediated inhibitory effect in the plasma one-stage bioassay by only ~50% (FIG. 5).

-23-

Despite its isolation several years ago, the physiologic function of PZ heretofore has remained uncertain. The results in Example I show that PZ slows the inhibition of factor Xa by antithrombin III in the presence of phospholipids and Ca^{++} ions, but also plays an important role in the inhibition of factor Xa by a novel plasma protein that is herein termed protein Z-dependent protease inhibitor, ZPI. PZ and/or its apparent interaction with factor Xa, however, may serve other functions. In this regard, it is important to note that inhibition of ZPI in the substrate plasma of the one-stage coagulation assay reduced the apparent inhibitory effect of the preincubation of PZ with phospholipids, Ca^{++} ions, and factor Xa by only ~50%.

The remaining PZ-mediated inhibitory effect could be related to its interference with the binding of other proteins to phospholipids (e.g. prothrombin), the slow dissociation of factor Xa from a putative factor Xa-PZ-phospholipid- Ca^{++} complex, or the presence of additional PZ-dependent coagulation inhibitors in plasma. The relatively slow association of PZ with phospholipids (11) is consistent with the time-dependent inhibitory effect of PZ during its incubation with phospholipids and Ca^{++} ions in the one-stage assay and, moreover, presumably also explains the absence of clotting time prolongation when PZ is added instead with the substrate plasma to the reaction.

-24-

The inhibition of factor Xa by presumed physiologic concentrations of ZPI requires the presence of phospholipids, Ca^{++} ions and PZ and appears to involve a stoichiometric complex of factor Xa, PZ and ZPI at the phospholipid surface. The apparent inhibition of factor Xa produced by ZPI, however, is considerably less when remaining factor Xa activity is measured using a small molecular weight chromogenic substrate (Spectrazyme Xa), than when remaining factor Xa activity is measured by bioassay. The cause of this discrepancy is not clear.

One explanation of the discrepancy could be the presence in the factor Xa preparations of degraded forms of factor Xa that retain activity against the chromogenic substrate but do not bind phospholipid and thus are not inhibited by ZPI and lack procoagulant activity. The disparity between the inhibitory effect measured by amidolytic assay and bioassay, however, was consistently seen with several factor Xa preparations whose amidolytic activity was bound by barium sulfate (>97%) and which by SDS-PAGE analysis contained a spectrum of ratios of α and β forms of factor Xa ($\alpha:\beta = 1:1$ to $1:4$) and <5% additionally degraded factor Xa. Moreover, the chromogenic activity of the factor Xa preparations was inhibited >99% by tissue factor pathway inhibitor (TFPI), suggesting that the residual chromogenic activity remaining following the interaction of factor Xa with ZPI was not due to a contaminating protease.

-25-

EXAMPLE II**Isolation and Cloning of ZPI cDNA****MATERIALS AND METHODS**

Materials: Fresh frozen human plasma was purchased from the Regional Red Cross (St. Louis, MO). Multiple human tissue RNA blot and human adult liver cDNA library were from Clontech (Palo Alto, CA); human fetal liver cDNA library was from Strategene (La Jolla, CA); nitrocellulose membrane from Schleicher & Schuell, Inc. (Keene, NH); PVDF membrane from Micron Separations, Inc. (Westborough, MA); ^{32}P - α dATP from NEN Life Scientific, Inc. (Boston, MA); and dNTPs from Pharmacia Biotech, Inc. (Piscataway, NJ). Taq DNA polymerase, DMEM culture medium, fetal calf serum and LipofectAMINE were from Gibco BRL, Life Technologies (Gaithersburg, MD). Antibiotic G418 (Geneticin) was purchased from Mediatech, Inc. (Herndon, VA). Chinese hamster ovary (CHO) cells were from the ATCC (Manassas, VA). ITS+3 media supplement, protease inhibitor cocktail, soybean trypsin inhibitor, aprotinin, and rabbit brain cephalin were from Sigma Chemical (St. Louis, MO). Factor X deficient plasma was from George King Biomedical, Inc. (Overland Park, KS). Prestained molecular weight standards for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) were purchased from Bio-Rad (Hercules, CA).

-26-

Proteins: PZ and ZPI were purified from human plasma as previously described (17). A mouse monoclonal anti-ZPI antibody (MC4249.2) was produced using established and previously reported techniques (18).

N-terminal amino acid sequencing of ZPI and trypsin-treated ZPI: Samples containing 20 μ g ZPI or 20 μ g ZPI that had been digested with trypsin (1:200 w/w) for 30 minutes at 22° C were reduced with 2-mercaptoethanol (5%) and separated by 12% SDS-PAGE and electro-transferred to a PVDF membrane. The membrane was stained for 10 minutes with 0.025% Coomassie Brilliant Blue R-250 in 10% methanol/7% acetic acid, washed with distilled water and allowed to air dry. Discernible protein bands of apparent molecular weight 72,000 for ZPI and 43,000 and 41,000 for trypsin-treated ZPI were cut from the membrane and sequenced by the Protein Chemistry Laboratory (Washington University, St. Louis, MO).

ZPI cDNA cloning: The N-terminal amino acid sequence of the two tryptic peptides derived from ZPI was highly homologous to the amino acid sequence predicted by the previously reported cDNA for rat regeneration-associated serpin (rasp-1, GeneBank Accession No. 2143953(see Results) (19). Nucleotide sequences derived from rasp-1 cDNA,

-27-

496-518 (ACCCAGGGTA GCTTTGCCTT CAT), SEQ ID NO: 3, and
805-825 (GTACATCATG GGCACCTTAA C), SEQ ID NO: 4,
were used as the basis for 5'- and 3'-primers, respectively,
in a PCR reaction to amplify a DNA fragment from a human fetal
liver cDNA library (Strategene). The PCR product, ~330 bp,
was cloned into pGEM-T Easy (Promega, Madison, WI) and was
found to be 80% homologous with rasp-1 cDNA by sequence
analysis. Following radiolabeling with ^{32}P - α dATP and random
priming, the PCR product was used as a probe to screen
approximately 2×10^5 plaque-forming units from a human liver
cDNA library (Clontech). Hybridization was performed at 42° C
in 5 x SSPE, 5 x Denhardt's solution, 1% SDS, 50% formamide,
and 100 $\mu\text{g/mL}$ denatured salmon sperm. Filters were washed
with 1 x SSC and 0.1% SDS solution at room temperature for 15
minutes and then washed three times with the same solution at
65° C for 30 minutes. The twenty-one positive clones that
remained after plaque purification contained cDNAs of four
different lengths. A representative of the longest cDNA was
sequenced in its entirety in both directions.

Northern blot analysis: ^{32}P -labeled full length ZPI cDNA was
used as a probe for analysis of a human multiple tissue
Northern blot membrane from Clontech (Palo Alto, CA)
containing 2 μg poly A+ RNA per sample. Hybridization was
performed under the stringent conditions suggested by the

-28-

manufacturer; autoradiography was allowed to proceed overnight.

In vitro expression of wild-type and altered forms of recombinant ZPI (rZPI): A 2.2 kb fragment of the ZPI cDNA was produced by treatment with Sac I and Hind III and inserted into the multiple cloning site of pBluescript KS II. This fragment contained part of the 5' untranslated region, the entire open reading frame, and the 3' untranslated region of the ZPI cDNA. A 2.3 kb fragment of pBluescript-ZPI was released by Pvu II treatment and inserted by blunt-end ligation into the EcoR V site of the expression vector pCMV (20) producing pCMV-ZPI(WT). This 2.3 kb DNA fragment contained: 1) ZPI cDNA beginning 120 bp upstream of ATG₆ and lacking the remainder of the 5' untranslated ZPI cDNA including ATG₁ - ATG₅; 2) the coding and 3' untranslated regions of ZPI cDNA; and 3) ~200 bp of pBluescript KS II DNA. In pCMV, expression is driven by the cytomegalovirus early promoter/enhancer.

PCR-based site-directed mutagenesis with pCMV-ZPI(WT) as template was used to change the codon for Y387 (TAT) in ZPI to that for alanine (GCT) or arginine (CGT). Mutations were confirmed by sequencing the ZPI cDNA between Nsi I (nt 1544) and Spe I (nt 1944) restriction sites which are upstream and downstream of the mutation site. These fragments were then

-29-

inserted in pCMV-ZPI(WT) at Nsi I - Spe I to produce pCMV-ZPI(Y387A) and pCMV-ZPI(Y387R). pCMV-ZPI(WT), pCMV-ZPI(Y387A) and pCMV-ZPI(Y387R) were co-transfected with pSV2neo into CHO cells using LipofectAMINE (GIBCO BRL) according to the manufacturer's instructions. Cell clones resistant to G418 were picked at three weeks and expanded. Non-transfected CHO cells and stable CHO clones expressing rZPI(WT), rZPI(Y387A), and rZPI(Y387R) were cultured in 5% CO₂ with DMEM and 10% fetal calf serum in six well culture plates (Costar, Corning, Inc., Corning, NY). After the cells reached confluence, the media was removed and the cells were washed three times with 5mL of DMEM before 1 ml of serum-free media consisting of DMEM with ITS+3 media supplement (insulin, transferrin, selenium, Sigma) was added to each well. After an additional 48 hrs. of culture, the conditioned media was collected, centrifuged (14,000 x g x 30 sec.) to remove cell debris, and analyzed by Western blotting and ZPI functional assay. In some experiments, aprotinin (1 µg/mL) and soybean trypsin inhibitor (2.5 µg/mL) were included in the serum-free media and a 1:10 dilution of protease inhibitor cocktail (Sigma) containing 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF) (100 mM), pepstatin A (1.5 mM), trans-expoxysuccinyl-L-leucyl-amido(4-guanidino)butane (E-64) (1.4 mM), bestatin (4 mM), leupeptin (2.2 mM), and aprotinin (80 µM) was added to the conditioned media at the time of its collection.

-30-

ZPI functional assay: A two-stage factor Xa inhibition assay was used to measure ZPI functional activity as previously described (17). Twenty μL rabbit brain cephalin ($75 \mu\text{M}$), 20 μL CaCl_2 (25 mM), 20 μL PZ (200 nM) or 20 μL HSA (0.1 M NaCl, 0.05 M Hepes, pH 7.4, with 1 mg/mL bovine serum albumin), 20 μL of the sample to be tested, and 20 μL factor Xa (1 nM) were incubated in the sample cup of a fibrometer at 37°C . After 60 sec., 50 μL cephalin ($75 \mu\text{M}$), 50 μL CaCl_2 (25 mM), and 50 μL factor X-deficient plasma were added in succession and the clotting time measured. ZPI activity was determined by comparing the clotting time with a standard curve produced by using various concentrations of purified ZPI derived from plasma. One μg of purified plasma ZPI was defined to possess 1000 milliunits (mU) of activity.

Western Blotting: SDS-polyacrylamide gel electrophoresis, the electro-transfer of proteins to nitrocellulose, and incubation of the blot with the monoclonal anti-ZPI antibody (MC4249.2) (10 $\mu\text{g}/\text{mL}$) were performed using previously described methods (21). Antibody binding to the blot was detected using horseradish peroxidase-labeled goat anti-mouse IgG antibodies (Sigma) and enhanced chemoluminescence (ECL) with Super Signal substrate (Pierce, Rockford, IL).

RESULTS

Isolation and Sequence of ZPI cDNA

In a search of publicly available protein and DNA databases, the N-terminal acid sequence of ZPI isolated from human plasma, LAPSPQSPEXXA (X=indeterminate), SEQ ID NO: 1, did not show significant sequence homology with previously reported gene products. However, the N-terminal sequence of peptides of 43 kDa and 41 kDa produced by trypsin treatment of ZPI were the same, NLELGLTQSFAFIHKDFDV, SEQ ID NO: 5, and showed 75% identity (16 of 20 residues) with an amino acid sequence predicted by the previously reported rat regeneration-associated serpin-1 (rasp-1) cDNA (19). Oligonucleotide primers based on rasp-1 cDNA sequence were used as PCR primers and a human fetal liver cDNA library (Stratagene) was used as a template to produce a ~330 bp probe for the subsequent isolation of ZPI cDNA (see *Methods*). Twenty-one positive plaques containing inserts of four different sizes were isolated from a human liver cDNA library (Clontech). The nucleotide sequence, SEQ ID NO: 7, and predicted amino acid sequence, SEQ ID NO: 8 of the longest ZPI cDNA insert, is shown in FIG. 6. Restriction mapping and limited sequence analysis of clones representative of the three shorter ZPI cDNA insert sizes suggest they are 5' truncated forms of the cDNA shown.

The 5' portion of the 2.44 kb ZPI cDNA contains six potential ATG translation start sites at nucleotides 156, 243,

-32-

259, 312, 347, and 467. The open reading frames following the first four ATG's encode 11, 22, 3, and 52 amino acids, respectively, before encountering stop codons. ATG₅ (underlined with dashes in FIG. 6) is in the same reading frame as ATG₆ and translation initiation at ATG₅ would add the forty amino acid sequence MSRSTQELLGYHCRLQDKLQEQEGSLAAEGRHSLASAADH, SEQ ID NO: 6, to the encoded protein.

Flanking nucleotides about the ATG codons, including ATG₅ and ATG₆, produce sequences that are not optimal for the initiation of translation (22). Nevertheless, ATG₆ is depicted as the initiator codon in FIG. 6 because additional tests (see below) showed it was sufficient for ZPI expression. On Northern analysis of a human multiple tissue blot, ~2.4 kb ZPI mRNA was strongly detected in liver, but undetectable in heart, lung, brain, spleen, testes and kidney (FIG. 7), suggesting that the liver is a major source of ZPI in vivo.

As depicted, the ZPI cDNA contains a 1335 bp open reading frame encoding a deduced protein of 444 amino acids. The predicted amino acid sequence has a typical 21 residue signal peptide that is followed by the N-terminal sequence of the purified ZPI protein. Five potential N-linked glycosylation sites are present. The nucleotide and predicted amino acid sequence of human ZPI are respectively 75% and 78% identical with

-33-

those of rat rasp-1, suggesting that ZPI represents the human homologue of this rat protein.

The ZPI amino acid sequence is also 25 - 35% homologous with other members of the serpin superfamily of protease inhibitors, including α_1 -antitrypsin, antithrombin, heparin cofactor II and protease nexin-1. The C-terminal region of ZPI shows the greatest similarity with the other members of the serpin superfamily, whereas the sequence of the N-terminal region of ZPI, which contains a very acidic domain (residues 26-43, FIG. 6), does not show significant homology with these other serpins.

The C-terminal amino acid sequences of ZPI, rasp-1, and certain other serpins are shown in FIG. 8. Based on this alignment, the putative P_1 residue at the reactive centers of human ZPI and rat rasp-1 is a tyrosine. Antitrypsin-related sequence (A1AU), an apparently non-transcribed DNA sequence highly homologous to that of antitrypsin and physically linked to the antitrypsin gene, also contains an aromatic residue (tryptophan) at the P_1 site (23,24). In common with many other serpins, the P_1' residue in ZPI is a serine, whereas the P_1' residue in rasp-1 is a cysteine.

-34-

Expression of recombinant ZPI

To confirm that the protein encoded by the isolated cDNA possesses ZPI activity and to determine the importance of Y387 to ZPI function, rZPI(WT) and two altered forms of ZPI, rZPI(Y387A) and rZPI(Y387R), were expressed in Chinese hamster ovary (CHO) cells. Western blot analysis of the respective serum-free conditioned medias showed that wild type and the altered forms of rZPI were present at similar concentrations (FIG. 9). However, while rZPI(WT) and rZPI(Y387A) migrated with the same apparent molecular mass as plasma-derived ZPI (72,000 Da), the bulk of rZPI(Y387R) migrated with a molecular mass of 68,000 Da. Attempts to reduce the apparent proteolytic degradation of rZPI(Y387R) by including aprotinin and soybean trypsin inhibitor in the serum-free culture media and adding a protease inhibitor cocktail to the collected conditioned media were unsuccessful (see *Methods*).

In a two-stage assay of PZ-dependent factor Xa inhibition, the serum-free conditioned media containing rZPI(WT) possessed substantial ZPI activity (375 mU/mL), whereas conditioned media containing rZPI(Y387A) lacked activity (<10 mU/mL) and conditioned media containing rZPI(387R) had markedly reduced activity (21 mU/mL) (FIG. 9).

-35-

Based on oligonucleotide and amino acid sequence homology, ZPI appears to be the human counterpart of rat rasp-1. Rasp-1 was initially identified as a gene whose transcription is increased 3- to 4-fold following subtotal hepatectomy in rats (19). However, rasp-1 expression is increased to a similar extent in sham-operated rats, suggesting that rasp-1 may be involved in the acute phase response. The rasp-1 gene product circulates in rat plasma with a reported molecular mass of ~50,000, whereas the molecular mass of plasma ZPI is ~72,000 (17,19). This apparent difference in the molecular size between the rat and human gene-products could be related to the extent of glycosylation. Constitutive expression of both rasp-1 (19) and ZPI genes is high in the liver and not detectable in brain, heart, lung, kidney, spleen, and testes by Northern analysis.

The ZPI cDNA is 2.44 kb in length and consistent with the smallest hybridizing species of ~2.4 kb noted in liver on Northern analysis (FIG. 7). Hybridizing bands of greater size likely represent incompletely processed forms of ZPI mRNA. The 5' region of the ZPI cDNA is relatively long (466 bp) and contains several potential ATG translation start codons. Four of these putative start codons are followed by termination codons, but the fifth ATG at nucleotide 347 is inframe with the ATG at nucleotide 467 that is tentatively designated as the authentic start codon. All these potential ATG initiation start sites are flanked by less than ideal nucleotide sequences (22).

-36-

The long 5' untranslated region, the presence of multiple upstream AUG codons that encode small open reading frames, and the lack of an optimal initiation sequence could all serve to suppress ZPI mRNA translation (22,25,26). Whether this is true, and whether an alternative form of ZPI is produced through translation initiation at the fifth AUG (nt 347), will require direct testing.

ZPI has 25 - 35% overall homology with other members of the serpin superfamily and its primary structure contains 40 of the 5' residues previously designated as essential for serpin tertiary structure (27). These conserved residues reside in the apolar core and the spine of serpin molecules. Amino acid alignment of ZPI and rasp-1 with other serpins suggests that the P₁ residue at their reactive centers is a tyrosine, which would set them apart from other serpins.

To confirm the role of Y387 in the inhibition of factor Xa by ZPI, altered forms of ZPI in which this residue was changed to an alanine or arginine were evaluated. rZPI(Y387A) was stable under the tissue culture conditions required for its expression and lacked PZ-dependent anti-factor Xa activity. In contrast to rZPI(WT), rZPI(Y387R) was apparently proteolytically degraded during the production of conditioned media despite the use of multiple protease inhibitors. The proteolytic event reduces the mass of ZPI by ~4,000 Da consistent with cleavage occurring

-37-

following R387, but the enzyme(s) responsible for this proteolysis is not known.

In sum, the tests with rZPI(Y387A) and rZPI(Y387R) suggest that Y387 is critical for PZ-dependent factor Xa inhibition and are consistent with the notion that Y387 is the P₁ residue at the reactive center of ZPI.

The coagulation inhibitors PZ, ZPI and combination of PZ and ZPI can be administered to a patient by conventional means, preferably in formulations with pharmaceutically acceptable diluents and carriers. The amount of the active component in the formulation which is administered must be an effective amount, i.e., an amount which is sufficient to inhibit coagulation. Parenteral administration of the active component such as in physiologic saline, buffered saline, e.g. phosphate-buffered saline (PBS), HEPES buffer and the like buffers, are illustrative. Other suitable formulations of the active component in pharmaceutically acceptable diluents and carriers in therapeutic dosage form can be prepared by reference to numerous general texts in the field well-known to the person skilled in the art, e.g., Remington's Pharmaceutical Sciences, Ed. Arthur Osol, 16th ed. 1980, Mack Publishing Co., Easton, PA., and 18th ed. 1990.

-38-

Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such other examples be included within the scope of the appended claims.

TABLE I

TABLE I. Apparent inhibition of factor Xa produced by incubation with PZ, cephalin and calcium ions before one-stage assay. PZ_T refers to thrombin-treated PZ (see Methods).

Incubation Period (sec.)		Apparent Inhibition (%)
Factor Xa	PZ	
120	0	0
120	15	50
120	30	61
120	60	72
120	90	76
120	120	78
120	PZ _T 120	0
15	120	70
30	120	71
60	120	73
90	120	76
120	120	78
120	120 w/o cephalin	0
120	120 w/o Ca++	0

SUBSTITUTE SHEET (RULE 26)

-40-

TABLE II
ZPI PURIFICATION

Step	Volume mL	Protein mg*	Activity units+ -----#	Specific Act. units/mg -----	Purification -fold -----	Yield %
Plasma	2300	144,740				---
Barium Absorption, NH ₄ SO ₄ fractionation	1430	59,730	1820	0.031	1.0	100
PEG fractionation	257	25,950	1720	0.066	2.2	94
S-Fast Flow, Concentration	25	191	1365	7.15	231	75
Mono-Q	10	50.2	1056	21.0	677	58
Heparin- Sephacrose	5.8	1.32	837	634	20,450	46
Mono-S	1.9	0.59	590	1000	32,800	32

* Protein determined assuming A₂₈₀ 1.0 = 1.0 mg/mL

+ Activity expressed in arbitrary units with 1.0 unit = 1 µg purified ZPI

Activity of plasma could not be determined due to thrombin generation in first stage of functional assay

SUBSTITUTE SHEET (RULE 26)

REFERENCES

1. Stenflo, J. Fernlund, P., Egan, W. & Roepstorff, P. (1974) *Proc. Natl. Acad. Sci. USA* 71, 2730-2733.
2. Nelsestuen, G.L., Zytkevich, T.H. & Howard, J.B. (1974) *J. Biol. Chem.* 249, 6347-6350.
3. Esmon, C.T., Suttie, J.W. & Jackson, C.M. (1975) *J. Biol. Chem.* 250d, 4094-4099.
4. Prowse, C.V. & Esnouf, M.P. (1977) *Biochem. Soc. Trans.* 5, 255-256.
5. Mattock, P. & Esnouf, M.P. (1973) *Nat. New Biol.* 242, 90-92.
6. Petersen, T.E., Thogersen, H.C., Sottrup-Jensen, L., Magnusson, S. & Jornvall, H. (1980) *FEBS Lett.* 114, 278-282.
7. Broze, Jr., G.J. & Miletich, J.P. (1984) *J. Clin. Invest.* 73, 933-938.
8. Miletich, J.P. & Broze, Jr., G.J. (1987) *Blood* 69, 1580-1586.
9. Sejima, H., Hayashi, T., Deyashiki, Y., Nishioka, J. & Suzuki, K. (1990) *Biochem Biophys. Res. Com.* 171, 661-668.
10. Ichinose, A., Takeya, H., Espling, E., Iwanaga, S., Kisiel, W. & Davie, E.W. (1990) *Biochem. Biophys. Res. Commun.* 172, 1139-1144.
11. McDonald, J.F., Shah, A.M., Schwalbe, R.A., Kisiel, W., Dahlback, B. & Nelsestuen, G.L. (1997) *Biochemistry* 36, 5120-5127.
12. Pratt, C.W. & Pizzo, S.V. (1987) *Biochemistry* 26, 2855-2863.
13. Broze, Jr., G.J. Warren, L.A., Novotny, W.F., Higuchi, D.A., Girard, J.J. & Miletich, J.P. (1988) *Blood* 71, 335-343.
14. Laemmle, M.K. (1970) *Nature* 227, 680-685.
15. Vaitukaitis, J.L. (1981) *Methods Enzymol.* 73, 46-52.

-42-

16. Ames, B.W. & Dubin, D.T. (1960) *J. Biol. Chem.* **235**, 769-775.
17. Han, X., Fiehler, R., and Broze, G.J., Jr. (1998) *Proc. Natl. Acad. Sci. USA* **95**:9250-9255.
18. Miletich, J.P. and Broze, G.J., Jr. (1987) *Blood* **69**:1580-1586.
19. New, L., Liu, K., Kamali, V., Plowman, G., Naughton, B.A., and Purchio, A.F. (1996) *Biochem. Biophys. Res. Commun.* **223**:404-412.
20. Smith, P.L., Skelton, T.P., Fiete, D., Dharmesh, S.M., Beranek, M.C., MacPhail, L., Broze, G.J., Jr. and Baenziger, J.U. (1992) *J. Biol. Chem.* **267**: 19140-19146.
21. Broze, G.J., Jr. and Miletich, J.P. (1985) *J. Clin. Invest.* **76**:937-946.
22. Kozak, M. (1986) *Cell* **44**:283-292.
23. Kelsey, G.D., Parkar, M., and Povey, S. (1988) *Ann. Hum. Genet.* **52**:151-160.
24. Bao, J.-J., Reed-Fourquet, L., Sifers, R.N., Kidd, V.J., and Woo, S.L. (1988) *Genomics* **2**:165-173.
25. Phelps, D.E., Hsiao, K.-M., Li, Y., Hu, N., Franklin, D.S., Westphal, E., Lee, E.Y., and Xiong, Y. (1998) *Mol. Cell. Biol.* **18**:2334-2343.
26. Stein, I., Itin, A., Einat, P., Skaliter, R., Grossman, Z., and Keshet, E. (1998) *Mol. Cell. Biol.* **18**:3112-3119.
27. Huber, R., and Carrell, R.W. (1989) *Biochemistry* **28**:8951-8966.

-43-

WHAT IS CLAIMED IS:

1. A purified and isolated human protein Z-dependent protease inhibitor characterized as:

- (a) having a molecular weight of about 72 kDa,
- (b) being a single chain protein with an N-terminal amino acid sequence of

Leu Ala Pro Ser Pro Gln Ser Pro Glu Thr
1 5 10

Pro Ala [SEQ ID NO:16], and

- (c) producing rapid inhibition of factor Xa in the presence of protein Z, calcium ions and cephalin.

2. A method of inhibiting factor Xa in serum or plasma comprising contacting said serum or plasma with an effective inhibitory amount of the human Protein Z-dependent protease inhibitor of Claim 1.

3. A purified and isolated DNA molecule comprising a nucleotide sequence encoding the 423 amino acid sequence of SEQ ID NO: 8.

4. A purified and isolated DNA molecule of Claim 3 having the nucleotide sequence of SEQ ID NO: 7.

5. A purified and isolated protein Z-dependent protease inhibitor having the 423 amino acid sequence of SEQ ID NO: 8.

6. A method of inhibiting factor Xa in serum or plasma comprising contacting said serum or plasma with an effective inhibitory amount of the human protein Z-dependent protease inhibitor of Claim 5.

-44-

7. A method of inhibiting blood coagulation in a patient in need thereof comprising administering to said patient a coagulation inhibitor selected from the group consisting of protein Z, ZPI and a combination of protein Z and ZPI in an amount sufficient to inhibit blood coagulation.

8. The method of Claim 7 in which the coagulation inhibitor is protein Z.

9. The method of Claim 7 in which the coagulation inhibitor is ZPI.

10. The method of Claim 9 in which the ZPI has the 423 amino acid sequence of SEQ ID NO:8.

11. The method of Claim 7 in which the coagulation inhibitor is a combination of protein Z and ZPI.

12. The method of Claim 11 in which the ZPI has the 423 amino acid sequence of SEQ ID NO:8.

13. A pharmaceutical composition comprising protein Z and ZPI in a pharmaceutically acceptable carrier or diluent.

14. The composition of Claim 13 in which the ZPI has the 423 amino acid sequence of SEQ ID NO:8.

1 / 9




FIG. 1

SUBSTITUTE SHEET (RULE 26)

2 / 9




FIG. 2

SUBSTITUTE SHEET (RULE 26)

3 / 9




FIG. 3

SUBSTITUTE SHEET (RULE 26)

4 / 9

FIG. 4A




FIG. 4B





FIG. 4C




FIG. 4D

SUBSTITUTE SHEET (RULE 26)

5 / 9




FIG. 5

SUBSTITUTE SHEET (RULE 26)

FIG. 6

6 / 9

ctggagtgagggtta 13
agaggcgaattatagacacaaaggggctcctctgcaggaaggaggccaagggaaagaggcttgaaaggcttgatat 88
ttcaccaccaccactcactgccggagtaagcaggtctcccttcccagggtgaggggagggcagggatgtgtgc 163
tgtcccagggtgagaagtggcaggtgagctggtgattccttactgccaggttctgtctaggaaggtgcgtcct 238
caccatgctggtggtgtcctagtccaggagcaccctcctgagctcctggcctagactccaaaggggtgggttagat 313
gagcaaaagacttttacaagaccttaggcgatataatgtccaggagcaccaggaattactgggctaccactgcaga 388
ctgcaggacaagctccaagaacaggaaggaagctctgcagctgaaggaggcactccttggcctccgcagccgat 463
cac atg aag gtg gtg cca agt ctc ctg ctc tcc gtc ctc ctg gca cag gtg tgg ctg 520/-4
M K V V P S L L L S V L L A Q V W L
gta ccc ggc ttg gcc ccc agt cct cag tcc cca gag acc cca gcc cct cag aac cag 577/16
V P G L A P S P O S P E T P A P Q N* Q
acc agc agg gta gtg cag gct ccc aag gag gaa gag gaa gat gag cag gag gcc agc 634/35
T S R V Q A P K E E E D E Q E A S
gag gag aag gcc agt gag gaa gag aaa gcc tgg ctg atg gcc agc agg cag cag ctt 691/54
E E K A S E E E K A W L M A S R Q Q L
gcc aag gag act tca aac ttc gga ttc agc ctg ctg cga aag atc tcc atg agg cac 748/73
A K E T S N F G F S L L R K I S M R H
gat ggc aac atg gtc ttc tct cca ttt ggc atg tcc ttg gcc atg aca ggc ttg atg 805/92
D G N M V F S P F G M S L A M T G L M
ctg ggg gcc aca ggg ccg act gaa acc cag atc aag aga ggg ctc cac ttg cag gcc 862/111
L G A T G P T E T Q I K R G L H L Q A
ctg aag ccc acc aag ccc ggg ctc ctg cct tcc ctc ttt aag gga ctc aga gag acc 919/130
L K P T K P G L L P S L F K G L R E T
ctc tcc cgc aac ctg gaa ctg ggc ctc aca cag ggg agt ttt gcc ttc atc cac aag 976/149
L S R N L E L G L T O G S F A F I H K
gat ttt gat gtc aaa gag act ttc ttc aat tta tcc aag agg tat ttt gat aca gag 1033/168
D F D V K E T F F N* L S K R Y F D T E
tgc gtg cct atg aat ttt cgc aat gcc tca cag gcc aaa agg ctc atg aat cat tac 1090/187
C V P M N F R N* A S Q A K R L M N H Y
att aac aaa gag act cgg ggg aaa att ccc aaa ctg ttt gat gag att aat cct gaa 1147/206
I N K E T R G K I P K L F D E I N P E
acc aaa tta att ctt gtg gat tac atc ttg ttc aaa ggg aaa tgg ttg acc cca ttt 1204/225
T K L I L V D Y I L F K G K W L T P F
gac cct gtc ttc acc gaa gtc gac act ttc cac ctg gac aag tac aag acc att aag 1261/244
D P V F T E V D T F H L D K Y K T I K
gtg ccc atg atg tac ggt gca ggc aag ttt gcc tcc acc ttt gac aag aat ttt cgt 1318/263
V P M M Y G A G K F A S T F D K N F R
tgt cat gtc ctc aaa ctg ccc tac caa gga aat gcc acc atg ctg gtg gtc ctc atg 1375/282
C H V L K L P Y Q G N* A T M L V V L M
gag aaa atg ggt gac cac ctc gcc ctt gaa gac tac ctg acc aca gac ttg gtg gag 1432/301
E K M G D H L A L E D Y L T T D L V E
aca tgg ctc aga aac atg aaa acc aga aac atg gaa gtt ttc ttt ccg aag ttc aag 1489/320
T W L R N M K T R N M E V F F P K F K
cta gat cag aag tat gag atg cat gag ctg ctt agg cag atg gga atc aga aga atc 1546/339
L D Q K Y E M H E L L R Q M G I R R I
ttc tca ccc ttt gct gac ctt agt gaa ctc tca gct act gga aga aat ctc caa gta 1603/358
F S P F A D L S E L S A T G R N L Q V
tcc agg gtt tta caa aga aca gtg att gaa gtt gat gaa agg ggc act gag gca gtg 1660/377
S R V L Q R T V I E V D E R G T E A V
gca gga atc ttg tca gaa att act gct tat tcc atg cct cct gtc atc aaa gtg gac 1717/396
A G I L S E I T A Y S M P P V I K V D
cgg cca ttt cat ttc atg atc tat gaa gaa acc tct gga atg ctt ctg ttt ctg ggc 1774/415
R P F H F M I Y E E T S G M L L F L G
agg gtg gtg aat ccg act ctc cta taa ttcaggacacgcataagcacttcgcgtgtagtagatgct 1840/423
R V V N* P T L L ***
gaatctgaggtatcaaacacacaggaataccgaatggatggcaggggagagtgttcctttttgttcttaacta 1915
gtttagggtgttctcaataaatacagtagtccccactttatctgagggggatataattcaagacccccagcagat 1990
gcctgaaacggtgtgacagtgtgaaccttatatatatttttctacacatacatacctatgataaagtftaatt 2065
tataaattaggcacagtaagagattaacaataataacaacattaagtaaaatgagttacttgaatgcaagcactg 2140
caataccataacagtcacaaactgattatagagaaggctactaagtgactcatggcgaggagcatagacagtgtg 2215
agacattgggcaaggggagaattcacatcctgggtgggacagagcaggacaatgcaagattccatcccactactc 2290
agaatggcatgctgcttaagacttttagattgtttatcttggaaatttttcatttaatgtttttggaccatggtt 2365
gaccatggttaactgagactgcagaaagcaaaaccatggataaggaggaggactactacaaaagcattaaattgata 2440
catatttttttaaaaaaaaaaaaaaaaaa

SUBSTITUTE SHEET (RULE 26)

7 / 9




FIG. 7

SUBSTITUTE SHEET (RULE 26)

ZPI	ER	GT	EA	VA	G	I	L	S	E	I	T	A	Y	S	M	P	P	-	-	V	I	K	V	D	R	P	F	H	F	M	I	Y	E	E	T	S	G	M	L	L	F	L	G	R	V	V	N	P	T	L	L
RASP-1	ER	GT	EV	VS	G	T	V	S	E	I	T	A	Y	C	M	P	P	-	-	V	I	K	V	D	R	P	F	H	F	I	I	Y	E	E	M	S	R	M	L	L	F	L	G	R	V	V	N	P	T	V	L
A1AT	EK	GT	EA	AG	A	M	F	L	E	A	I	P	M	S	I	P	P	-	-	E	V	K	F	N	K	P	F	V	F	L	M	I	E	Q	N	T	K	S	P	L	F	M	G	K	V	V	N	P	T	Q	K
A1AU	EK	GT	EA	TG	A	P	H	L	E	E	K	A	W	S	K	Y	Q	-	-	T	V	M	F	N	R	P	F	L	V	I	I	K	E	Y	I	T	N	F	P	L	F	I	G	K	V	V	N	P	T	Q	K
AT-III	EE	GS	EA	AA	S	T	A	V	V	I	A	G	R	S	L	N	P	N	R	V	T	F	K	A	N	R	P	F	L	V	I	E	V	P	L	N	T	I	I	F	M	G	R	V	A	N	P	C	V	K	
HC-II	EE	GT	QA	TT	V	T	T	V	G	F	M	P	L	S	T	O	V	-	-	R	F	T	V	D	R	P	F	L	F	L	I	Y	E	H	R	T	S	C	L	L	F	M	G	R	V	A	N	P	S	R	S
PN-I	ED	GT	KA	SA	A	T	T	A	I	L	I	A	R	S	S	P	P	-	-	W	F	I	V	D	R	P	F	L	F	F	I	R	H	N	P	T	G	A	V	L	F	M	G	Q	I	N	K	P			

FIG. 8

9 / 9




FIG. 9






INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/15, C07K 14/81, A61K 38/36, 38/55		A3	(11) International Publication Number: WO 99/60126
			(43) International Publication Date: 25 November 1999 (25.11.99)
(21) International Application Number: PCT/US99/07040		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 13 May 1999 (13.05.99)		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(30) Priority Data: 60/086,571 19 May 1998 (19.05.98) US		(88) Date of publication of the international search report: 2 March 2000 (02.03.00)	
(71) Applicant (for all designated States except US): WASHINGTON UNIVERSITY [US/US]; One Brookings Drive, St. Louis, MO 63130 (US).			
(72) Inventor; and (75) Inventor/Applicant (for US only): BROZE, George, J., Jr. [US/US]; Washington University School of Medicine, Dept. of Internal Medicine, Division of Hematology, Barnes-Jewish Hospital of St. Louis, 216 S. Kingshighway Boulevard, St. Louis, MO 63110 (US).			
(74) Agents: MEYER, Scott, J. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680 (US).			

(54) Title: PROTEIN Z-DEPENDENT PROTEASE INHIBITOR

(57) Abstract

The disclosure describes the purification and isolation of a novel human protein Z-dependent protease inhibitor (ZPI) from plasma characterized as having a molecular weight of about 72 kDa, being a single chain protein with an N-terminal amino acid sequence of LAPSPQSPETPA, and which produces a rapid inhibition of factor Xa in the presence of human protein Z (PZ), calcium ions and cephalin. The disclosure further describes the isolation and cloning of the ZPI cDNA from a human cDNA library. The ZPI cDNA is 2.44 kb in length and has an open reading frame that encodes the 423 residue mature ZPI protein and a 21 residue signal peptide. PZ, ZPI and the combination of PZ and ZPI are used to inhibit blood coagulation.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

Int. Patent Application No
PC 99/07040

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/15 C07K14/81 A61K38/36 A61K38/55

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US BROZE G J JR ET AL: "HUMAN PROTEIN Z." retrieved from STN, accession no. 1984:296223 BIOSIS Database accession no. BA78:32703 XP002115294 abstract & J CLIN INVEST, (1984) 73 (4), 933-938., cited in the application</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 December 1999

Date of mailing of the international search report

07.01.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van der Schaal, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/07040

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ICHINOSE A ET AL: "Amino acid sequence of human protein Z, a vitamin K-dependent plasma glycoprotein." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1990 NOV 15) 172 (3) 1139-44., XP002115292 cited in the application ---</p>	
A	<p>EP 0 551 084 A (ALPHA THERAPEUTIC CORP) 14 July 1993 (1993-07-14) ---</p>	
A	<p>EP 0 419 099 A (MERCK & CO INC) 27 March 1991 (1991-03-27) ---</p>	
A	<p>EP 0 543 240 A (MOCHIDA PHARM CO LTD) 26 May 1993 (1993-05-26) page 6, paragraph 1 page 17, paragraph 3 ---</p>	
A	<p>WO 96 39640 A (UNIV CALIFORNIA) 12 December 1996 (1996-12-12) ---</p>	
P,X	<p>HAN X ET AL: "Isolation of a protein Z -dependent plasma protease inhibitor." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1998 AUG 4) 95 (16) 9250-5., XP002115293 the whole document ---</p>	1-14
X	<p>ECKERT, COLETTE ET AL: "The Effect of Bovine Protein Z on Plasma Clotting Reactions." CIRCULATION, (1994) VOL. 90, NO. 4 PART 2, PP. 1619. MEETING INFO.: 67TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION DALLAS, TEXAS, USA NOVEMBER 14-17, 1994 , XP000857666 see abstract 3337 ---</p>	7,8
A	<p>KEMKES-MATTHES B ET AL: "Protein Z deficiency: a new cause of bleeding tendency." THROMBOSIS RESEARCH, (1995 JUL 1) 79 (1) 49-55. , XP000857663 ---</p>	7,8
A	<p>RICHTER, A. ET AL: "Oral anticoagulant therapy: Extremely low protein Z levels." ANNALS OF HEMATOLOGY, (1998) VOL. 76, NO. SUPPL. 1, PP. A100. MEETING INFO.: 42ND ANNUAL MEETING OF THE GESELLSCHAFT FUER THROMBOSE- UND HAEMOSTASEFORSCHUNG (SOCIETY FOR THROMBOSIS AND HEMOSTASIS RESEARCH) FRANKFURT/MAIN, GERMANY FEBRUARY 25-28, 1998, XP000857672 see abstract P291 -----</p>	7,8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/07040

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 2 6 7-12 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-6 9-14 completely, 7 partially

Protein Z dependent protease inhibitor, its encoding nucleotide sequence and their use

2. Claims: 8 completely, 7 partially

Use of Protein Z as inhibitor of blood coagulation

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PATENT S 99/07040

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0551084	A	14-07-1993	US 5319072 A CA 2085953 A JP 6128296 A	07-06-1994 11-07-1993 10-05-1994
EP 0419099	A	27-03-1991	AT 133962 T AU 639257 B AU 6224790 A CA 2024697 A DE 69025247 D DE 69025247 T DK 419099 T IE 70759 B JP 3178997 A US 5328997 A US 5239058 A	15-02-1996 22-07-1993 14-03-1991 08-03-1991 21-03-1996 12-09-1996 11-03-1996 30-12-1996 02-08-1991 12-07-1994 24-08-1993
EP 0543240	A	26-05-1993	AU 661515 B AU 2820992 A CA 2082226 A JP 6025289 A US 5679770 A US 5589360 A US 5451659 A	27-07-1995 13-05-1993 09-05-1993 01-02-1994 21-10-1997 31-12-1996 19-09-1995
WO 9639640	A	12-12-1996	US 5581256 A AU 6145796 A CA 2224117 A EP 0830618 A JP 11506824 T	03-12-1996 24-12-1996 12-12-1996 25-03-1998 15-06-1999

THIS PAGE BLANK (USPTO)